While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition ...

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia ...

Both small animal models and microphysiological systems gain in sophistication and value as they expedite in vivo preclinical testing.

Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, ...

Fibronectin fibers lose tension in invasive breast cancer, unlike in healthy or DCIS tissues, suggesting a mechanical marker ...

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of ...

CD34-lineage cells differentiate into T cells and enhance tertiary lymphoid organ formation in allograft artery. A, Experimental scheme depicting the tamoxifen-induced CD34-lineage cell labeling, ...

BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...